2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2261

Association Between Musculoskeletal Pain, Fat Mass and Fat Free Mass: Results from a Population-Based Study
Abstract Number: 2516

Association Between Primary Sjögren’s Syndrome and Pregnancy Outcome: A Systematic Review and Meta-Analysis
Abstract Number: 3047

Association Between Red Blood Cell Distribution Width and Disease Activity in Behcet’s Disease
Abstract Number: 2400

Association Between Serum Urate and Osteoarthritis Progression in a Non-Obese Cohort
Abstract Number: 573

Association Between Three Measures of Oral Glucocorticoid Exposure and Potential Adverse Events Among Patients with Rheumatoid Arthritis
Abstract Number: 2785

Association of Anti-Glutamate Receptor Subunit NR2 Antibody and Psychiatric Disorder in Patients with Primary Sjögren Syndrome
Abstract Number: 2947

Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 1852

Association of Antibodies to the NR1 Subunit of N-Methyl-D-Aspartate Receptors with Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 1005

Association of Baseline Knee Sagittal Dynamic Joint Stiffness during Gait and 2-Year Cartilage Damage Progression in Knee Osteoarthritis (OA)
Abstract Number: 1458

Association of Chronic, Extreme Elevation of Serum IL-18 with the Development of Macrophage Activation Syndrome in a Cohort of Autoinflammatory Disease Patients: A Potential Diagnostic Biomarker?
Abstract Number: 1869

Association of CLEC16A with SLE in a Large Multi-Ancestry Cohort and Implication in B-Cell Receptor Signaling
Abstract Number: 267

Association of CXCL10 and CXCL13 Levels with Disease Activity and Cutaneous Manifestation in Active Adult-Onset Still’s Disease
Abstract Number: 109

Association of HLA-G and Leukocyte Immunoglobulin-like Receptor A3 Polymorphisms with the Susceptibility to Pulmonary Hyterpention in Systemic Sclerosis
Abstract Number: 2633

Association of Medication Beliefs, Self-Efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis
Abstract Number: 1883

Association of Myocardial Abnormalities with Disease Characteristic and Brain Natriuretic Peptide (BNP) in Systemic Sclerosis without Cardiac Symptoms As Assessed Using Cardiac Magnetic Resonance Imaging; A Prospective Multi Center Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].